Özgeçmiş

hepatit

Prof. Dr. Yılmaz Çakaloğlu’nun özgeçmişi

Gastroenteroloji-Hepatoloji Uzmanı (Sindirim Sistemi ve Karaciğer Hastalıkları)



1958 yılı Yusufeli (Artvin) doğumludur. İlk, orta ve lise tahsilini Merzifon, Bursa ve İstanbul'da tamamladı. 1974-75 döneminde İstanbul Haydarpaşa Lisesinden mezun oldu. 1981 yılında Uludağ Üniversitesi Tıp Fakültesinden mezun oldu.

1982-1986 arasında İstanbul Tıp Fakültesi İç Hastalıkları Anabilim Dalında uzmanlık eğitimini tamamlayarak İç Hastalıkları Uzmanı oldu (Uzmanlık tezi: "Serum prealbumininin karaciğer fonksiyon testi olarak değerlendirilmesi"). 1986 yılında İstanbul Tıp Fakültesi İç Hastalıkları Anabilim Dalı, Gastroenterohepatoloji Bilim Dalında başasistan olarak çalışmaya başladı (mecburi hizmetini bu statüde tamamladı). 1987-1988 yıllarında askerlik hizmetini (16 ay) İç Hastalıkları Uzmanı olarak İstanbul Deniz Hastahanesi İç Hastalıkları kliniğinde tamamladı ve önceki görevine döndü.

1989 yılı Ekim ayında İç Hastalıkları Doçenti oldu.

1991 yılı Temmuz ayında "Kronik Asemptomatik HBsAg Taşıyıcılarının Prospektif Uzun Süreli Takip Sonuçları" başlıklı Gastroenterohepatoloji yan dal uzmanlık tezi ile Gastroenteroloji Uzmanı oldu.

1991 Temmuz-1992 Eylül arasında "Institute of Liver Studies, King’s College School of Medicine” (Londra, İngiltere) isimli kurumda "Clinical Research Fellow" pozisyonunda çalışarak, başta karaciğer transplantasyonu olmak üzere hepatobiliyer hastalıklar konusunda klinik çalışmalar ve araştırma faaliyetlerinde bulundu.

1992 yılından itibaren İTF Karaciğer Nakli programında çalıştı.

1996 yılında İç Hastalıklarında Profesör kadrosuna atandı.

14 Şubat 2008 tarihinde 26 yıllık İTF İç Hastalıkları Kliniği çalışanı olarak emekliliğe adımını attı. Halen Şişli Memorial Hastanesi Gastroenteroloji-Hepatoloji Bölüm Başkanı ve Karaciğer Nakli Hepatoloji Sorumlusu olarak aktif mesleki hayatını sürdürmektedir.

16 Ekim 2011 tarihinde Türk Karaciğer Araştırmaları Derneği başkanlığına seçilmiştir. 2011-2013 yıllarında bu görevini sürdürmüştür.

24 Ocak 2012’de Türk Karaciğer Vakfı başkanı olmuştur.

Genel gastroenteroloji-hepatoloji eğitimi ve pratiği yanında, araştırma konuları daha çok hepatobiliyer hastalıklar (viral hepatitler, siroz ve komplikasyonları, karaciğer nakli ağırlıklı) üzerinde yoğunlaşmıştır.

Evli ve iki çocuk babası olup, İngilizce bilmektedir.


ÜYESİ OLDUĞU TIP KURULUŞLARI


Türk Karaciğer Vakfı Başkanı

Türk Karaciğer Araştırmaları Derneği

Türk Gastroenteroloji Derneği

Organ Nakli Kuruluşları Koordinasyon Derneği (Karaciğer Çalışma Grubu)

EASL (European Association for the Study of the Liver)

AASLD (American Association for the Study of Liver Diseases)

AGA (American Gastroenterological Association)

European Board of Gastroenterology


Büyük bölümü Türkçe ve bir bölümü İngilizce olarak toplam 250 civarında yayını vardır. Uluslararası tam metin yayınlarının listesi ektedir.

İç Hastalıkları ve Gastroenteroloji Uzmanlık tezlerinin tez hocası ve mentörü çok kıymetli hocası Prof. Dr. Atilla ÖKTEN’dir.



ULUSLARARASI YAYINLARI (“Pubmed”) LİSTESİ


1: Tozun N, Ozdogan O, Cakaloglu Y, Idilman R, Karasu Z, Akarca U, Kaymakoglu S, Ergonul O. Seroprevalence of hepatitis B and C virus infections and risk factors in Turkey: A fieldwork TURHEP study. Clin Microbiol Infect. 2015 Jul 7. pii: S1198-743X(15)00690-4. doi: 10.1016/j.cmi.2015.06.028. [Epub ahead of print] PubMed PMID: 26163105.


2: Yankol Y, Mecit N, Kanmaz T, Cimsit B, Cakaloglu Y, Acarli K, Kalayoglu M. Lessons Learned From Review of a Single Center Experience With 500 Consecutive Liver Transplants in a Region With Insufficient Deceased-Donor Support. Exp Clin Transplant. 2015 May 30. doi: 10.6002/ect.2014.0170. [Epub ahead of print] PubMed PMID: 26030810.


3: Brouwer WP, Sonneveld MJ, Tabak F, Simon K, Cakaloglu Y, Akarca US, Zeuzem S, Ferenci P, Heathcote JE, de Knegt RJ, Boonstra A, Hansen BE, Janssen HL. Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B. Aliment Pharmacol Ther. 2014 Oct;40(7):811-8. doi: 10.1111/apt.12910. Epub 2014 Aug 11.

PubMed PMID: 25109699.


4: Arends P, Rijckborst V, Zondervan PE, Buster E, Cakaloglu Y, Ferenci P, Tabak F, Akarca US, Simon K, Sonneveld MJ, Hansen BE, Janssen HL. Loss of intrahepatic HBsAg expression predicts sustained response to peginterferon and is reflected bypronounced serum HBsAg decline. J Viral Hepat. 2014 Dec;21(12):897-904. doi:

10.1111/jvh.12218. Epub 2014 Jan 20. PubMed PMID: 24444353.


5: Uyanikoglu A, Kaymakoglu S, Danalioglu A, Akyuz F, Ermis F, Pinarbasi B, Demir K, Besisik F, Cakaloglu Y. Durability of sustained virologic response in chronic hepatitis C. Gut Liver. 2013 Jul;7(4):458-61. doi: 10.5009/gnl.2013.7.4.458. Epub2013 Jun 20. PubMed Central PMCID: PMC3724035. PubMed PMID: 23898387


6: Yonal O, Ibrisim D, Songur Y, Cakaloglu Y, Tuncer K, Kirimlioglu H, Ozdil S. Primary malignant melanoma of the esophagus. Case Rep Gastroenterol. 2013 Jun 25;7(2):272-6. doi: 10.1159/000353637. Print 2013 May. PubMed PMID: 23898233;

PubMed Central PMCID: PMC3724127.


7: Kabaçam G, Dalekos GN, Çakaloğlu Y, Zachou K, Bock T, Erhardt A, Zeuzem S, Tabak F, Yalçin K, Bozdayi AM, Dienes HP, Bozkaya H, Manns M, Wedemeyer H, Yurdaydin C. Pegylated interferon-based treatment in patients with advanced liver disease due to chronic delta hepatitis. Turk J Gastroenterol. 2012;23(5):560-8. PubMed PMID: 23161302.


8: Rijckborst V, Ferenci P, Akdogan M, Pinarbasi B, ter Borg MJ, Simon K, Flisiak R, Akarca US, Raptopoulou-Gigi M, Verhey E, van Vuuren AJ, Boucher CA, Hansen BE,Janssen HL; PARC Study Group. Long-term follow-up of hepatitis B eantigen-negative patients treated with peginterferon α-2a: progressive decrease in hepatitis B surface antigen in responders. Eur J Gastroenterol Hepatol. 2012Sep;24(9):1012-9. PubMed PMID: 22668876.


9: Mederacke I, Yurdaydin C, Großhennig A, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, Zachou K, Chatzikyrkou C, Bozkaya H, Dalekos GN, Manns MP, Wedemeyer H; Hep-Net/International Delta Hepatitis Study Group. Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection. J Viral Hepat. 2012 Jun;19(6):387-95. doi:10.1111/j.1365-2893.2011.01560.x. Epub 2011 Dec 19. PubMed PMID: 22571900.


10: Mederacke I, Yurdaydin C, Dalekos GN, Bremer B, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Dienes HP, Manns MP, Wedemeyer H; Hep-Net/International Delta Hepatitis Study Group. Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-α2a treatment. Antivir Ther. 2012;17(2):305-12. doi: 10.3851/IMP1926. Epub 2011 Oct 24. PubMed PMID: 22293066.


11: Sonneveld MJ, Rijckborst V, Cakaloglu Y, Simon K, Heathcote EJ, Tabak F, Mach T, Boucher CA, Hansen BE, Zeuzem S, Janssen HL. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype. Antivir Ther. 2012;17(1):9-17. doi: 10.3851/IMP1887. PubMed PMID: 22267464.


12: Rijckborst V, Hansen BE, Ferenci P, Brunetto MR, Tabak F, Cakaloglu Y, Lanza AG, Messina V, Iannacone C, Massetto B, Regep L, Colombo M, Janssen HL, Lampertico P. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol. 2012 May;56(5):1006-11. doi: 10.1016/j.jhep.2011.12.007. Epub 2012 Jan 13. PubMed PMID: 22245886.


13: Sonneveld MJ, Wong VW, Woltman AM, Wong GL, Cakaloglu Y, Zeuzem S, Buster EH, Uitterlinden AG, Hansen BE, Chan HL, Janssen HL. Polymorphisms near IL28B andserologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B. Gastroenterology. 2012 Mar;142(3):513-520.e1. doi: 10.1053/j.gastro.2011.11.025.Epub 2011 Nov 19.

PubMed PMID: 22108195.


14: Akyüz F, Cakaloğlu Y, Pinarbaşi B, Demir K, Akyüz U, Ozdil S, Beşişik F,Boztaş G, Mungan Z, Kaymakoğlu S. Anticoagulant therapy and Budd-Chiari syndrome: is it successful? Hepatogastroenterology. 2011 May Jun;58(107-108):900-3.

PubMed PMID: 21830413.


15: Wedemeyer H, Yurdaydìn C, Dalekos GN, Erhardt A, Çakaloğlu Y, Değertekin H, Gürel S, Zeuzem S, Zachou K, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP; HIDIT Study Group. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011 Jan 27;364(4):322-31. doi: 10.1056/NEJMoa0912696. PubMed PMID: 21268724.


16: Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Akarca US, Flisiak R, Verhey E, Van Vuuren AJ, Boucher CA, ter Borg MJ, Janssen HL. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology.

2010 Aug;52(2):454-61. doi: 10.1002/hep.23722. PubMed PMID: 20683945.


17: Rijckborst V, ter Borg MJ, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, Simon K, Raptopoulou-Gigi M, Ormeci N, Zondervan PE, Verhey E, van Vuuren AJ, Hansen BE, Janssen HL; PARC Study Group. A randomized trial of peginterferon alpha-2a with or without ribavirin for HBeAg-negative chronic hepatitis B. Am JGastroenterol. 2010 Aug;105(8):1762-9. doi: 10.1038/ajg.2010.186. Epub 2010 May11. PubMed PMID: 20461068.


18: Ahishali E, Demir K, Ahishali B, Akyuz F, Pinarbasi B, Poturoglu S, Ibrisim D, Gulluoglu M, Ozdil S, Besisik F, Kaymakoglu S, Boztas G, Cakaloglu Y, Mungan Z, Canberk Y, Okten A. Electron microscopic findings in non-alcoholic fatty liver disease: is there a difference between hepatosteatosis and steatohepatitis? J

Gastroenterol Hepatol. 2010 Mar;25(3):619-26. doi: 10.1111/j.1440-1746.2009.06142.x. PubMed PMID: 20370732.


19: Yonal O, Akyuz F, Demir K, Ciftci S, Keskin F, Pinarbasi B, Uyanikoglu A, Issever H, Ozdil S, Boztas G, Besisik F, Kaymakoglu S, Cakaloglu Y, Mungan Z, Okten A. Decreased prohepcidin levels in patients with HBV-related liver disease: relation with ferritin levels. Dig Dis Sci. 2010 Dec;55(12):3548-51. doi:10.1007/s10620-010-1183-8. Epub 2010 Mar 18. PubMed PMID: 20238243.


20: Akyüz F, Beşişik F, Pinarbaşi B, Demir K, Kaymakoğlu ST, Cakaloğlu Y, Sever MS, Okten A. The quality of life in hemodialysis patients with chronic hepatitis C virus infection. Turk J Gastroenterol. 2009 Dec;20(4):243-6. PubMed PMID: 20084566.


21: Zachou K, Yurdaydin C, Drebber U, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, Gurel S, Zeuzem S, Bozkaya H, Schlaphoff V, Dienes HP, Bock TC, Manns MP, Wedemeyer H; HIDT-1 Study Group. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int. 2010 Mar;30(3):430-7. doi:10.1111/j.1478-3231.2009.02140.x. Epub 2009 Oct 16.

PubMed PMID: 19840253.


22: Idilman R, Kaymakoglu S, Oguz Onder F, Ahishali E, Bektas M, Cinar K, Pinarbasi B, Karayalcin S, Badur S, Cakaloglu Y, Mithat Bozdayi A, Bozkaya H, Okten A, Yurdaydin C. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients. J Viral Hepat. 2009 Apr;16(4):279-85. doi: 10.1111/j.1365-2893.2009.01074.x. Epub 2009 Feb 12. PubMed PMID: 19222742.


23: Cakaloğlu Y, Akyüz F, Bozaci M, Ibrişim D, Pinarbaşi B, Demir K, Kaymakoğlu S, Beşişik F, Badur S, Okten A. Prevalence and clinical significance of SEN-H virus in chronic hepatitis B, C and delta infections in Turkey. Turk J Gastroenterol. 2008 Jun;19(2):104-8. PubMed PMID: 19110665.


24: Liaw YF, Gane E, Leung N, Zeuzem S, Wang Y, Lai CL, Heathcote EJ, Manns M, Bzowej N, Niu J, Han SH, Hwang SG, Cakaloglu Y, Tong MJ, Papatheodoridis G, Chen Y, Brown NA, Albanis E, Galil K, Naoumov NV; GLOBE Study Group. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology. 2009 Feb;136(2):486-95. doi: 10.1053/j.gastro.2008.10.026. Epub 2008 Nov 1. PubMed PMID: 19027013.


25: Ibrişim D, Cevikbaş U, Akyüz F, Poturoğlu S, Ahishali E, Güllüoğlu M, Demir K, Beşişik F, Boztaş G, Ozdil S, Cakaloğlu Y, Mungan Z, Okten A, Kaymakoğlu S. Intestinal metaplasia in portal hypertensive gastropathy: a frequent pathology. Eur J Gastroenterol Hepatol. 2008 Sep;20(9):874-80. doi: 10.1097/MEG.0b013e3282fc7380. PubMed PMID: 18794601.


26: Pinarbasi B, Kaymakoglu S, Matur Z, Akyuz F, Demir K, Besisik F, Ozdil S, Boztas G, Cakaloglu Y, Mungan Z, Okten A. Are acquired hepatocerebral degeneration and hepatic myelopathy reversible? J Clin Gastroenterol. 2009 Feb;43(2):176-81. doi: 10.1097/MCG.0b013e318150d399. PubMed PMID: 18698265.


27: Pinarbasi B, Onel D, Cosan F, Akyuz F, Dirlik N, Cakaloglu Y, Badur S, Besisik F, Demir K, Okten A, Kaymakoglu S. Prevalence and virological features of occult hepatitis B virus infection in female sex workers who work uncontrolled in Turkey. Liver Int. 2009 Feb;29(2):227-30. doi: 10.1111/j.1478-3231.2008.01809.x. Epub 2008 Jul 24. PubMed PMID: 18662283.


28: Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology. 2008 Aug;135(2):459-67. doi: 10.1053/j.gastro.2008.05.031. Epub 2008 May 15. PubMedPMID: 18585385.


29: ter Borg MJ, Hansen BE, Herrmann E, Zeuzem S, Cakaloglu Y, Karayalcin S,Flisiak R, van' t Veen A, de Man RA, Schalm SW, Janssen HL, Haagmans BL; HBV99-01 Study Group. Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B. Antivir Ther. 2007;12(8):1285-94.

PubMed PMID: 18240868.


30: Akyuz F, Kaymakoglu S, Demir K, Aksoy N, Karaca C, Danalioglu A, Onel D, Badur S, Besisik F, Cakaloglu Y, Okten A. Lamivudine monotherapy and lamivudine plus interferon alpha combination therapy in HBeAg negative chronic hepatitis B not responding to previous interferon alpha monotherapy. Acta Gastroenterol Belg.2007 Jan-Mar;70(1):20-4.

PubMed PMID: 17619534.


31: Demir K, Akyuz F, Ozdil S, Aksoy N, Kaymakoglu S, Poturoglu S, Akyüz U, Besisik F, Boztas G, Mungan Z, Cevikbas U, Cakaloglu Y, Okten A. What is the reason of elevated alanine aminotransferase level in HBeAg negative patients with low viremia: NAFLD or chronic hepatitis? Ann Hepatol. 2007 Apr-Jun;6(2):92-6. PubMed PMID: 17519831.


32: Kaymakoglu S, Oguz D, Gur G, Gurel S, Tankurt E, Ersöz G, Ozenirler S, Kalayci C, Poturoglu S, Cakaloglu Y, Okten A. Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B. Antimicrob Agents Chemother. 2007 Aug;51(8):3020-2. Epub 2007 May 21. PubMed PMID: 17517832; PubMed Central PMCID: PMC1932537.


33: Akyüz F, Demir K, Ozdil S, Aksoy N, Poturoğlu S, Ibrişim D, Kaymakoğlu S, Beşişik F, Boztaş G, Cakaloğlu Y, Mungan Z, Cevikbaş U, Okten A. The effects of rosiglitazone, metformin, and diet with exercise in nonalcoholic fatty liver disease. Dig Dis Sci. 2007 Sep;52(9):2359-67. Epub 2007 Apr 11. PubMed PMID:17429734.


34: Kaymakoglu S, Danalioglu A, Demir K, Karaca C, Akyuz F, Onel D, Badur S, Cevikbas U, Besisik F, Cakaloglu Y, Okten A. Long-term results of interferon alpha monotherapy in patients with HBeAg-negative chronic hepatitis B. Dig Dis Sci. 2007 Mar;52(3):727-31. PubMed PMID: 17237999.


35: Ibrisim D, Cakaloglu Y, Akyuz F, Karadag A, Ozdil S, Besisik F, Mungan Z, Okten A. Treatment of hepatic hydrothorax with terlipressin in a cirrhotic patient. Scand J Gastroenterol. 2006 Jul;41(7):862-5. PubMed PMID: 16785202.


36: van Zonneveld M, Zondervan PE, Cakaloglu Y, Simon C, Akarca US, So TM, Flink HJ, de Man RA, Schalm SW, Janssen HL; HBV 99-01 Study Group. Peg-interferonimproves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine. Liver Int. 2006 May;26(4):399-405. PubMed PMID: 16629642.


37: Karaca C, Cakaloğlu Y, Demir K, Ozdil S, Kaymakoğlu S, Badur S, Okten A. Risk factors for the transmission of hepatitis C virus infection in the Turkish population. Dig Dis Sci. 2006 Feb;51(2):365-9.

PubMed PMID: 16534682.


38: Akyüz F, Polat N, Kaymakoglu S, Aksoy N, Demir K, Beşişik F, Badur S, Cakaloglu Y, Okten A. Intrahepatic and peripheral T-cell responses in genotype 1b hepatitis C virus-infected patients with persistently normal and elevated aminotransferase levels. World J Gastroenterol. 2005 Dec 7;11(45):7188-91. PubMed PMID: 16437670.


39: Danalioğlu A, Kaymakoğlu S, Mungan Z, Karaca C, Demir K, Durakoğlu Z, Beşişik F, Boztaş G, Cakaloğlu Y, Okten A. Efficacy of cyclosporin in severe ulcerative colitis attack. Turk J Gastroenterol. 2002 Sep;13(3):130-3. PubMed PMID: 16378293.


40: Güvenç S, Kaymakoğlu S, Gürel N, Karşidağ K, Demir K, Dinçer D, Kekik C, Salman S, Yilmaz T, Beşişik F, Cakaloğlu Y. The prevalence of manifest and latent celiac disease in type 1 diabetes mellitus. Turk J Gastroenterol. 2002 Jun;13(2):103-7. PubMed PMID: 16378286.


41: Dincer D, Besisk F, Demirkol O, Demir K, Kaymakoglu S, Cakaloglu Y, Okten A. Relationships between hemodynamic alterations and Child-Pugh Score in patientswith cirrhosis. Hepatogastroenterology. 2005 Sep-Oct;52(65):1521-5. PubMed PMID: 16201110.


42: van Zonneveld M, Flink HJ, Verhey E, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Hansen BE, Schalm SW, JanssenHL; HBV 99-01 Study Group. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther. 2005 May 1;21(9):1163-71. PubMed PMID: 15854180.


43: Boztas G, Mungan Z, Ozdil S, Akyüz F, Karaca C, Demir K, Kaymakoglu S, Besisik F, Cakaloglu Y, Okten A. Pneumatic balloon dilatation in primary achalasia: the long-term follow-up results. Hepatogastroenterology. 2005Mar-Apr;52(62):475-80.

PubMed PMID: 15816461.


44: Tahan V, Karaca C, Yildirim B, Bozbas A, Ozaras R, Demir K, Avsar E, Mert A, Besisik F, Kaymakoglu S, Senturk H, Cakaloglu Y, Kalayci C, Okten A, Tozun N. Sexual transmission of HCV between spouses. Am J Gastroenterol. 2005 Apr;100(4):821-4. PubMed PMID: 15784025.


45: Kaymakoglu S, Karaca C, Demir K, Poturoglu S, Danalioglu A, Badur S, Bozaci M, Besisik F, Cakaloglu Y, Okten A. Alpha interferon and ribavirin combination therapy of chronic hepatitis D. Antimicrob Agents Chemother. 2005 Mar;49(3):1135-8. PubMed PMID: 15728914; PubMed Central PMCID: PMC549218.


46: Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW; HBV 99-01 Study Group; Rotterdam Foundation for Liver Research. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive

chronic hepatitis B: a randomised trial. Lancet. 2005 Jan 8-14;365(9454):123-9. PubMed PMID: 15639293.


47: Danalioglu A, Kaymakoglu S, Cakaloglu Y, Demir K, Karaca C, Durakoglu Z, Bozaci M, Badur S, Cevikbas U, Okten A. Efficacy of alpha interferon therapy for lamivudine resistance in chronic hepatitis B. Int J Clin Pract. 2004

Jul;58(7):659-61. PubMed PMID: 15311721.


48: Danalioglu A, Cakaloglu Y, Karaca C, Aksoy N, Akyuz F, Ozdil S, Demir K, Besisik F, Boztas G, Mungan Z, Kaymakoglu S, Okten A. Terlipressin and albumin combination treatment in hepatorenal syndrome. Hepatogastroenterology. 2003 Dec;50 Suppl 2:ccciii-cccv. PubMed PMID: 15244209.


49: Danalioglu A, Kaymakoglu S, Mungan Z, Karaca C, Demir K, Durakoglu Z, Besisik F, Boztas G, Cakaloglu Y, Okyen A. Cyclosporin for severe ulcerative colitis attacks. Hepatogastroenterology. 2003 Dec;50 Suppl 2:ccxcviii-ccc.

PubMed PMID: 15244207.


50: Ozdil S, Demir K, Boztas G, Danalioglu A, Karaca C, Akyüz F, Aksoy N, Kaymakoglu S, Mungan Z, Besisik F, Cakaloglu Y, Okten A. Crohn's disease; analysis of 105 patients. Hepatogastroenterology. 2003 Dec;50 Suppl 2:cclxxxvii-ccxci.

PubMed PMID: 15244204.


51: Ozdil S, Akyüz F, Pinarbasi B, Demir K, Karaca C, Boztas G, Kaymakoglu S, Mungan Z, Besisik F, Cakaloglu Y, Okten A. Ulcerative colitis: analyses of 116 cases (do extraintestinal manifestations effect the time to catch remission?).Hepatogastroenterology. 2004 May-Jun;51(57):768-70. PubMed PMID: 15143912.


52: Danalioğlu A, Poturoğlu S, Güngör Güllüoğlu M, Demir K, Beşişik F, Cakaloğlu Y, Cevikbaş U, Okten A. Budd-Chiari syndrome in a young patient with celiac sprue: a case report. Turk J Gastroenterol. 2003 Dec;14(4):262-5. PubMed PMID:15048602.


53: Kaymakoglu S, Kahraman T, Kudat H, Demir K, Cakaloglu Y, Adalet I, Dincer D, Besisik F, Boztas G, Sözen AB, Mungan Z, Okten A. Hepatopulmonary syndrome in noncirrhotic portal hypertensive patients. Dig Dis Sci. 2003 Mar;48(3):556-60.

PubMed PMID: 12757170.


54: Besisik F, Karaca C, Akyüz F, Horosanli S, Onel D, Badur S, Sever MS, Danalioglu A, Demir K, Kaymakoglu S, Cakaloglu Y, Okten A. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. J Hepatol. 2003 Apr;38(4):506-10. PubMed PMID: 12663244.


55: Dinçer D, Besisik F, Sahin E, Demir K, Tuncer I, Cevikbas U, Mungan Z, Kaymakoglu S, Boztas G, Ozdil S, Cakaloglu Y, Okten A. Intestinal metaplasia of the gastric cardia: a study from Turkey. Hepatogastroenterology. 2002 Jul-Aug;49(46):1153-6.

PubMed PMID: 12143225.


56: Karaca C, Kaymakoglu S, Uyar A, Karayay S, Gurler N, Demir K, Dincer D, Tuncer L, Boztas G, Cakaloglu Y, Okten A. Intestinal bacterial overgrowth in liver cirrhosis: is it a predisposing X factor for spontaneous ascitic infection? Am J Gastroenterol. 2002 Jul;97(7):1851. PubMed PMID: 12135057.


57: Dinçer D, Okten A, Kaymakoglu S, Besisik F, Demir K, Tuncer I, Bozaci M, Turkoglu S, Cevikbas U, Cakaloglu Y. Persistently normal alanine transaminase levels in chronic C hepatitis: what does it tell us? Hepatogastroenterology. 2001 Sep-Oct;48(41):1397-400. PubMed PMID: 11677973.


58: Demir K, Kaymakoglu S, Besisik F, Durakoglu Z, Ozdil S, Kaplan Y, Boztas G, Cakaloglu Y, Okten A. Solitary pancreatic tuberculosis in immunocompetent patients mimicking pancreatic carcinoma. J Gastroenterol Hepatol. 2001Sep;16(9):1071-4. PubMed PMID: 11595077.


59: Demir K, Okten A, Kaymakoglu S, Dincer D, Besisik F, Cevikbas U, Ozdil S, Bostas G, Mungan Z, Cakaloglu Y. Tuberculous peritonitis--reports of 26 cases, detailing diagnostic and therapeutic problems. Eur J Gastroenterol Hepatol. 2001 May;13(5):581-5. PubMed PMID: 11396540.


60: Dinçer D, Besisik F, Oğuz F, Sever MS, Kaymakoglu S, Cakaloglu Y, Demir K, Türkoglu S, Carin M, Okten A. Genes of major histocompatibility complex class II influence chronic C hepatitis treatment with interferon in hemodialysis patients. Int J Artif Organs. 2001 Apr;24(4):212-4. PubMed PMID: 11394702.


61: Gürel S, Demir K, Kaymakoglu S, Boztas G, Cakaloglu Y, Besisik F, Okten A. A rare complication of endoscopic injection sclerotherapy: thrombosis of subclavian vein. Hepatogastroenterology. 2000 Sep-Oct; 47(35):1319-21.

PubMed PMID: 11100341.


62: Besisik F, Sever MS, Dincer D, Cevikbas U, Türkoglu S, Cakaloglu Y, Kaymakoglu S, Okten A. Serial measurements of serum transaminases in renal transplant recipients with chronic hepatitis C: do they reflect disease severity? Clin Transplant. 2000 Dec;14(6):529-32. PubMed PMID: 11127304.


63: Gürel S, Beşişk F, Demir K, Mungan Z, Kaymakoğlu S, Boztaş G, Cakaloğlu Y, Yeğinsü O, Okten A. After the eradication of Helicobacter pylori infection, relapse is a serious problem in Turkey. J Clin Gastroenterol. 1999 Apr; 28(3):241-4.

PubMed PMID: 10192611.


64: Kaymakoğlu S, Demir K, Cakaloğlu Y, Tuncer I, Dinçer D, Gürel S, Okten A. Combination therapy with hepatitis B vaccine and interferon alfa in chronic hepatitis B. Am J Gastroenterol. 1999 Mar;94(3):856-7. PubMed PMID: 10086686.


65: Kaymakoglu S, Cakaloglu Y, Demir K, Türkoglu S, Badur S, Gürel S, Beşişik F, Cevikbaş U, Okten A. Is severe cryptogenic chronic hepatitis similar to autoimmune hepatitis? J Hepatol. 1998 Jan;28(1):78-83. PubMed PMID: 9537867.


66: Saxena R, Hytiroglou P, Atillasoy EO, Cakaloglu Y, Emre S, Thung SN. Coexistence of hereditary hemorrhagic telangiectasia and fibropolycystic liver disease. Am J Surg Pathol. 1998 Mar;22(3):368-72. PubMed PMID: 9500780.


67: Kaymakoglu S, Eraksoy H, Okten A, Demir K, Calangu S, Cakaloglu Y, Boztas G, Besisik F. Spontaneous ascitic infection in different cirrhotic groups: prevalence, risk factors and the efficacy of cefotaxime therapy.

Eur J Gastroenterol Hepatol. 1997 Jan;9(1):71-6.


68: Kaymakoğlu S, Okten A, Cakaloğlu Y, Boztaş G, Beşişik F, Taşçioğlu C, Yalçin S. Hypogonadism is not related to the etiology of liver cirrhosis. J Gastroenterol. 1995 Dec;30(6):745-50.

PubMed PMID: 8963392.


69: Cakaloglu Y, Devlin J, O'Grady J, Sutherland S, Portmann BC, Heaton N, Tan KC, Williams R. Importance of concomitant viral infection during late acute liver allograft rejection. Transplantation. 1995 Jan 15;59(1):40-5. PubMed PMID: 7839426.


70: Cakaloglu Y, Tredger JM, Devlin J, Williams R. Importance of cytochrome P-450IIIA activity in determining dosage and blood levels of FK 506 and cyclosporine in liver transplant recipients. Hepatology. 1994 Aug; 20(2):309-16. PubMed PMID: 7519161.


71: Cakaloglu Y, Marinos G, Marsden J, Peters TJ, Williams R, Tredger JM. Localization of cyclosporin A absorption in rat small bowel and the effect of bile. Clin Sci (Lond). 1993 Jun;84(6):675-9.

PubMed PMID: 8334815.


72: Cakaloglu Y, Kaymakoglu S, Okten A, Besisik F, Badur S, Yalcin S. Horizontal transmission of hepatitis B virus infection. J Hepatol. 1992 May;15(1-2):265-6.

PubMed PMID: 1506648.


73: Cakaloglu Y, Okten A, Yalcin S. Serum-ascites albumin concentration gradient (A-GRAD) in the prediction of portal hypertension in ascitic patients. Gastroenterology. 1991 May;100(5 Pt 1):1484-5.

PubMed PMID: 2013400.